US regulators have placed a partial clinical hold on all trials assessing venetoclax for multiple myeloma after a higher than expected number of patient deaths. More: FDA places partial hold on clinical trials of venetoclax for multiple myeloma Source: News
read moreSage Therapeutics has the first-ever approval for a prescription drug for postpartum depression, thanks to the FDA’s Tuesday nod for Zulresso. But it also has a number of big challenges ahead. More: Sage wins OK for depression drug Zulresso. Up
read moreAbbVie and Roche are looking to move key oncology drug Venclexta deeper into the blood cancer arena, but their ambitions just took a hit. After flagging deaths in a phase 3 multiple myeloma trial, the FDA put all of Venclexta’s
read moreStarboard Value published a 197-page presentation tearing apart the proposed merger between Bristol-Myers Squibb and Celgene. But it lacked a “smoking gun,” an analyst wrote, so the tie-up will likely go through. More: Without 'smoking gun,' BMS, Celgene deal will
read moreBayer’s nailing down the details on its long-anticipated animal health sale, reports say. It’s planning an auction, for one thing, and the deal’s drawing interest from top private equity and buyout players. And if bidders don’t offer up enough for
read moreJust a week after Roche’s Tecentriq became the first immuno-oncology agent the FDA approved for triple-negative breast cancer, the anti-PD-L1 drug has clinched another first-in-class approval—this time in lung cancer. More: In another I-O first for Roche, Tecentriq nabs blockbuster
read more© 1994 - 2026 B.M. Pharmaceuticals